TimesSquare Capital Management LLC Has $13.61 Million Stake in Merus (NASDAQ:MRUS)

TimesSquare Capital Management LLC increased its position in Merus (NASDAQ:MRUS) by 49.5% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 272,435 shares of the biotechnology company’s stock after buying an additional 90,215 shares during the period. TimesSquare Capital Management LLC’s holdings in Merus were worth $13,611,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Allspring Global Investments Holdings LLC acquired a new position in Merus during the first quarter worth $72,000. nVerses Capital LLC grew its stake in shares of Merus by 750.0% in the third quarter. nVerses Capital LLC now owns 1,700 shares of the biotechnology company’s stock worth $85,000 after acquiring an additional 1,500 shares during the last quarter. US Bancorp DE bought a new position in shares of Merus during the 3rd quarter worth about $103,000. SG Americas Securities LLC bought a new stake in shares of Merus in the first quarter valued at about $108,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in shares of Merus by 24.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,467 shares of the biotechnology company’s stock valued at $118,000 after purchasing an additional 489 shares during the period. 96.14% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $85.00 target price on shares of Merus in a report on Friday, November 1st. UBS Group initiated coverage on Merus in a research note on Thursday, October 24th. They set a “buy” rating and a $72.00 price objective on the stock. Guggenheim upped their price target on shares of Merus from $93.00 to $111.00 and gave the company a “buy” rating in a report on Tuesday, October 1st. Canaccord Genuity Group upgraded Merus to a “strong-buy” rating in a research note on Thursday, July 25th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $67.00 target price on shares of Merus in a report on Thursday, July 25th. One investment analyst has rated the stock with a sell rating, eleven have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $86.70.

Merus Price Performance

Shares of Merus stock opened at $54.50 on Monday. The firm has a 50-day moving average of $50.99 and a 200-day moving average of $51.80. Merus has a 52-week low of $22.01 and a 52-week high of $61.61.

Merus (NASDAQ:MRUS) last announced its earnings results on Thursday, October 31st. The biotechnology company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.05). Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%. The business had revenue of $11.77 million for the quarter, compared to analyst estimates of $9.11 million. As a group, equities analysts forecast that Merus will post -3.88 earnings per share for the current year.

Merus Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.